Institute of Nuclear Energy Research

Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan

Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.o.c

National Atomic Research Institute

Institute of Nuclear Energy Research Atomic Energy Council, R.o.c.

Ming-Hsin Li

Wuu-Jyh Lin

Su-Jung Chen

Shih-Ying Lee

Sheng-Nan Lo

Shih-Wei Lo

Chyng-Yann Shiue

Ming-Wei Chen

Chun-Fang Feng

Han-Chih Chang

Chih-Hsien Chang

Hsin-Han Hsieh

Ther-Jen Ting

I-Lea Dai

Jin-Jenn Lin

Wei-Lin Lo

Te-Wei Lee

Ting-Shien Duh

Shu-Pei Chiu

Te-Wei Li

Tain-Shi Zen

Yuan-Ruei Huang

Han-Hsiang Chu

Wei-Ming Li

Ting Shien Duh

Wuu-Jyn Lin

Kai-Hung Cheng

Hsin-EII Wang

Chun-Yi Wu

Shih-Min Wang

Cheng-Hung Chien

Jun-Chieh Tsai

Wun-Shen Lan

The invention features a novel precursor provided for radioisotope labeling with ligands for specific binding of prostate-specific membrane antigen (PSMA) for prostate cancer diagnosis and treatment, and the pharmacophore of a PSMA inhibitor composed of three molecules of glutamic acid, urea and lysine is provided with three variable linkers based on pharmacological activity of the PSMA inhibitor for labeling with radioactive nucleus Ga-67, Ga-68, In-111, Lu-177, Cu-64, or Y-90 through a chelating agent for imaging analysis of human tumor models of prostate cancer and serving as a PSMA-targeted radioligand therapy for prostate cancer diseases.

PSMA targeted radiotherapy medicine and preparation method thereof

The present disclosure relates to a compound or its salt thereof targeting fibroblast activation protein, its preparation methods and uses, especially the compound represented by formula (I) D-R1-R2-A-R' or its salt thereof, and its preparation methods and its uses.

Compound or its salt thereof targeting fibroblast activation protein, its preparation methods and its uses thereof

Disclosed herein are kits and methods for preparing radiopharmaceuticals. The kits and methods of the present disclosure can prepare the radiopharmaceuticals without using a heater and computer monitoring equipment. The kit includes a frozen crystal reaction vial, a reagent vial and a labeling holder, wherein the labeling holder contains a heating bag that can heat up to a high temperature of at least 95&#xb0; C. by adding an aqueous solution.

Kits and methods for preparing radiopharmaceuticals

A system and method for monitoring cardiovascular and brain functions in combination with a physiological detection device, which uses a smart wearable device to detect physiological data such as heart rate and pulse pressure of a user, and transmits the physiological data to an arithmetic function. An electronic device in which a preset function and a calculation formula are built in, and the physiological data can be converted into corresponding determination parameters to monitor the possibility and risk of cardiovascular diseases and neurodegenerative diseases.

System for monitoring cardiovascular and brain function in combination with physiological detection device and method thereof

The present invention provides a radioactive labeling method for neuropeptide Y (NPY) compound and a mammalian diagnostic radioactive targeting medicine with NPY peptide being modified at position 27to 36, and after binding with the chelating agent and labeling the radiation nucleusGaGaGaLu orIn to provide a radioactive targeting medicine for multi-type breast cancer diagnosis and treatment.

Radioactive labeling method for neuropeptide Y derivative compound and medicine for multi-type breast cancer therapy thereof

Method provided for labeling a nuclear medicine for imaging tracing, comprising a labeling precursor of the HDAC inhibitor BNL-26 (C22H23N3O) and the derivatives that are separated into two classes. The first class comprises a BNL-26 (C22H23N3O) and derivatives BNL-26a (C21H21N3O), BNL-26b (C22H22N2O), and other compounds of the labeling precursors which are categorized into two parts, the first part includes BNL-26-CH2CH2OTs (C31H33N3O4S), BNL-26a-CH2CH2OTs (C30H31N3O4S), and BNL-26b-CH2CH2OTs (C31H32N2O4S), which provides labeling precursor through &#x2014;CH2CH2OTs structure, and the second part includes pre-BNL-26 (C28H34N3O3B), pre-BNL-26a (C27H32N3O3B), pre-BNL-26b (C28H33N2O3B), which provides labeling precursor through 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl structure. The second class includes BNL-26 (C22H23N3O) indole/indoline, which provides a series of derivative labeling precursors derived from a secondary amide bond.

Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases

The present invention relates to a group of compounds for nuclear medicine imaging through F-18 labeled histone acetylation inhibitors (HDACi) of indole or indoline benzoyl amine and its derivatives, and provides a series of nuclear medicine imaging agents that bind with HDAC overexpression in vivo for diagnosis of malignant tumors discovered in the nuclear medicine imaging tracing.

Compound and analogues for tracing histone acetylation inhibitors PET imaging for diagnosis and treatment of tumors

An automated test apparatus for risk and integrity testing for pharmaceutical filtration membranes, including at least the following components: a liquid injection inlet, a pump, a fluid pressure gauge, a gas pressure gauge, a plurality of solenoid valves, a plurality of membranes, a gas pressure regulator valve, a pharmaceutical product bottle, and a bubble generation bottle. The automated test apparatus of the present invention is controlled by computer software in connection with an automatic pharmaceutical synthesis apparatus for automated testing. In use of the automated test apparatus of the present invention, it needs only to start the operating system of the automated test apparatus for membrane risk and integrity test after the completion of the automatic pharmaceutical synthesis. The membrane risk and integrity test can be accomplished in a short time by measuring pressures of gas and liquid with pressure gauges deposed online concurrently.

Automated test apparatus for testing risk and integrity of pharmaceutical filtration membranes and method thereof

A method of synthesizing a compound of imaging agent with HDAC (histone deacetylase) inhibitor consists of two parts, the first part of the method is to provide the inhibitor of HDAC with a compound of imaging agent that includes HDAC inhibitor BNL-26 (CHNO) and its analogs to be labeled with radionuclide F-18, producing a series of new nuclear medicine tracers: BNL-26-CHCH18F, BNL-26a-CHCH18FF, BNL-26b-CHCH18F, BNL-26c-CHCH18F and BNL-26d-CHCH18F. These nuclear medicine with imaging agents can be used as a tracer in vivo binding to over-expression HDAC and produce a HDAC nuclear medicine imaging effect to serve for clinical diagnosis. The second part of the method is to provide a slightly adjusted a structural framework of BNL-26 and use pyridine to substitute the benzene ring of the BNL-26 structure, and then synthesize with other substituent to produce a series of additional 30 more HDAC inhibitors, named from Iner-1 to Iner-30 compounds.

Compounds of imaging agent with HDAC inhibitor for treatment of Alzheimer syndrome and method of synthesis thereof

The preparation method of radiation-sensitive copolymer carrier for coating radiated nanoparticles and/or chemotherapy drugs includes forming a nanosphere by diselenide block copolymers and DSPE-PEG-biomarkers to coat chemotherapy drugs and/or radiated nanoparticles that can be released from the opened nanosphere by protons penetrating tissue during proton therapy. The treatment effect of proton therapy is enhanced by two ways of using the radiated nanoparticles released from an opened nanosphere to produce nuclear fission with the protons for releasing electrons to destroy cancer cells of tumor and the chemotherapy drugs released from the opened nanosphere for distributing among tissue to kill the cancer cells of the tumor.

Preparation method of radiation sensitive copolymer carrier for coating radiated nanoparticles and chemotherapy drugs

The present invention relates to a system of real time micro hot cell image control for radiopharmaceutical automatic synthesizing apparatus including at least one CCD camera, a plurality of radioactivity detector, a logic control device, a computer interface control device. The plurality of radioactivity detector are connected to the logic control device, and the logic control device sends a corresponding location code to the computer interface control device when the detected radioactivity value is greater than the threshold value for selecting a nearest CCD camera and sending the taken image of the location to the computer interface control device for monitoring whether the automatic production line of radiopharmaceuticals is kept in normal operation.

Monitoring system of real time image control for radiopharmaceutical automatic synthesizing apparatus in a micro hot cell

The invention provides an automatic synthesizer apparatus and method for producing radiopharmaceutical tumor imaging agent Gallium-68-DOTATATE with one button control process to effectively isolate the medication in vials from the contamination of environment and manual operations, saving the costs of investment in production with alleviation of the critical standard required for the environmental equipments to be used for production.

Automatic synthesizer apparatus for producing radiopharmaceutical tumor imaging agent Gallium-68-DOTATATE and method thereof

A method of purification for recycling of gallium-69 isotopes includes processes of proton irradiation and dissolution for a silver alloy plating target with gallium-69. After the proton irradiation and dissolution, a high concentration elution liquid of gallium-69 and germanium-68 is obtained by washing through an ion-exchange resin to filter out gallium-69 solution, followed by neutralizing precipitation, drying, and sintering treatments to obtain a gallium oxide. The gallium oxide can be dissolved to produce a solid target, and the washing processes can be repeated. The solid target after use can be placed in recycling again. This method is not only implemented to reduce the cost of production and comply with recycling notion nowadays, but also enhance efficiency in the practical application of radioisotopes.

Method of purification for recycling of gallium-69 isotope

A Gallium-68 (Ga-68) radioisotope generator includes a generating column and a citrate eluent. The generating column is at least partially filled with an ion-exchange resin with glucamine groups to absorb germanium-68 (Ge-68) and Ga-68 radioisotopes. The citrate eluent is added into the generating column to desorb the Ga-68 radioisotope and form an eluent containing the Ga-68 radioisotope in the form of Ga-68 citrate. A method for generating Ga-68 radioisotope is also disclosed.

Gallium-68 radioisotope generator and generating method thereof

The invention is related a novel structure for Ga-68 radionuclide generator. It allows two washing solutions to pass through two Ge-68 absorbents to wash out different chemical forms of Ga-68 nuclide. The invention comprises the first method that will withdraw hydrochloric acid solution from the washing bottle and pass it through inorganic resin absorbing column to produce the radioisotope solution of Ga-68 gallium chloride, and the second method that will allow the radioisotope solution of Ga-68 gallium citrate to pass the organic resin absorbing column and then the silica-gel cartridge, and be washed by the hydrochloric acid solution to obtain the radioisotope solution of Ga-68 gallium chloride.

Growing community of inventors

Taoyuan County, Taiwan

Ming-Hsin Li